BioRestorative Therapies Inc. recently held an investor presentation highlighting their advancements in regenerative medicine. The company is actively developing therapies using brown adipose derived stem cells and bone marrow derived mesenchymal stem cells, with their projects at various stages from preclinical to mid-stage clinical trials. The presentation also introduced BioCosmeceuticals, which applies secretome biologics based technology for cosmetic applications. The leadership team, including Lance Alstodt, Chairman & CEO, and Francisco Silva, Vice President of R&D, shared insights into their robust R&D efforts and ongoing commercialization plans. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on September 04, 2025, and is solely responsible for the information contained therein.